Olejnik Agnieszka, Płonka Joanna, Kuliczkowski Wiktor, Mysiak Andrzej, Gierlotka Marek, Bil-Lula Iwona D
Department of Medical Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland.
Department of Cardiology, Institute of Medical Sciences, University of Opole, Opole, Poland.
Cardiol J. 2025;32(4):380-391. doi: 10.5603/cj.98861. Epub 2025 May 26.
Klotho is a transmembrane and secretory protein and acts as a co-receptor for fibroblast growth factor 23 (FGF23). This study aimed to analyse the concentration of Klotho and FGF23 proteins in patients with myocardial infarction (MI).
The study group comprised 129 patients diagnosed with acute coronary syndrome (ACS), who were referred for further invasive diagnostics (MI group). Blood samples were collected at 4 time points: at admission, and 6h, 24h, and between 24-48h post-admission. The criteria for the control subjects (n = 30) were no declaration of MI and ACS (non-MI group). Klotho and FGF23 concentrations in plasma were tested by ELISA at each time point.
The concentration of soluble Klotho in the MI group was increased at admission, 6h and 24 h post-admission, and then normalized at 24-48h. Klotho concentration was also significantly increased in patients with ST-segment elevation MI (STEMI) only at admission, in comparison to non-ST-segment elevation MI (NSTEMI). The concentration of FGF23 in the MI group was higher at admission, 6h and 24h post-admission, and continued to increase after 24-48 h. There was an increase in FGF23 concentration in the STEMI group at 24-48h post-admission, in comparison to NSTEMI.
The concentrations of Klotho and FGF23 in plasma were higher in patients with MI and changed over time. Thus, Klotho and FGF23 may be recognized as new factors in the diagnosis and/or monitoring of ACS, as well as novel therapeutic targets.
α-klotho是一种跨膜分泌蛋白，作为成纤维细胞生长因子23（FGF23）的共受体发挥作用。本研究旨在分析心肌梗死（MI）患者中α-klotho和FGF23蛋白的浓度。
研究组包括129例诊断为急性冠状动脉综合征（ACS）并接受进一步侵入性诊断的患者（MI组）。在4个时间点采集血样：入院时、入院后6小时、24小时以及入院后24 - 48小时之间。对照组（n = 30）的标准为无MI和ACS声明（非MI组）。在每个时间点通过酶联免疫吸附测定（ELISA）检测血浆中α-klotho和FGF23的浓度。
MI组可溶性α-klotho的浓度在入院时、入院后6小时和24小时升高，然后在24 - 48小时恢复正常。与非ST段抬高型心肌梗死（NSTEMI）相比，仅ST段抬高型心肌梗死（STEMI）患者入院时α-klotho浓度也显著升高。MI组FGF23的浓度在入院时、入院后6小时和24小时较高，在24 - 48小时后继续升高。与NSTEMI相比，STEMI组入院后24 - 48小时FGF23浓度升高。
MI患者血浆中α-klotho和FGF23的浓度较高且随时间变化。因此，α-klotho和FGF23可被视为ACS诊断和/或监测的新因素以及新的治疗靶点。
